This study is researching better treatment options for Metastatic Non-Small Cell Lung Cancer (NSCLC), a type of lung cancer that has spread to other parts of the body. Doctors will compare two groups: one group will receive durvalumab and tremelimumab combined with chemotherapy, and the other group will receive pembrolizumab with chemotherapy. These drugs help the immune system fight cancer cells. The study includes people with specific cancer-related genetic changes, like STK11, KEAP1, or KRAS mutations. Participants will receive the treatment through an IV infusion (a slow injection into a vein) and will visit the trial site every 3 to 4 weeks for up to 4 years. During visits, participants will have check-ups, give blood and urine samples, and have scans taken of their tumors. It's important to note that participants and doctors will know which treatment is being given. The study aims to see how long patients live, how long their cancer stops growing, and how well tumors respond to the treatment.

• Participants will be involved for up to 4 years, with visits every 3 to 4 weeks.
• Participants will receive treatment through IV infusions.
• All participants and doctors will know which treatment is given.